相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors
Paraskevi Diamanti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis
Sheila Bohler et al.
HAEMATOLOGICA (2021)
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
Esperanza M. Algarin et al.
HAEMATOLOGICA (2020)
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Guillaume Richard-Carpentier et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma
Victoria M. Smith et al.
HAEMATOLOGICA (2020)
BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells
Sehar Afreen et al.
CELL DEATH & DISEASE (2020)
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Aleksandr Ianevski et al.
NUCLEIC ACIDS RESEARCH (2020)
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
Marco Haselager et al.
BLOOD (2020)
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
Donia M. Moujalled et al.
BLOOD ADVANCES (2020)
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
Clara Alcon et al.
CELL DEATH & DISEASE (2020)
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Shruti Bhatt et al.
CANCER CELL (2020)
The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
Zhaodong Li et al.
LEUKEMIA (2019)
Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia
Ernesto Diaz-Flores et al.
CANCER RESEARCH (2019)
Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation
Brice Mouttet et al.
HAEMATOLOGICA (2019)
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
K. Fischer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
Felix Seyfried et al.
CELL DEATH & DISEASE (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
Larissa Ewald et al.
CELL DEATH & DISEASE (2019)
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies
Andrew E. Place et al.
FUTURE ONCOLOGY (2018)
Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
Ryan S. Soderquist et al.
NATURE COMMUNICATIONS (2018)
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
Sean Caenepeel et al.
CANCER DISCOVERY (2018)
NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
Yuxuan Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E. Tron et al.
NATURE COMMUNICATIONS (2018)
Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use
Margs S. Brennan et al.
BLOOD (2018)
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Jerry M. Adams et al.
CELL DEATH AND DIFFERENTIATION (2018)
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
Viktoras Frismantas et al.
BLOOD (2017)
iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
Jeremy Ryan et al.
BIOLOGICAL CHEMISTRY (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Sarah E. Alford et al.
CANCER RESEARCH (2015)
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Joan Montero et al.
CELL (2015)
The BCL-2 protein family, BH3-mimetics and cancer therapy
A. R. D. Delbridge et al.
CELL DEATH AND DIFFERENTIATION (2015)
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Joel D. Leverson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G. S. Choudhary et al.
CELL DEATH & DISEASE (2015)
Analysis of drug combinations: current methodological landscape
Julie Foucquier et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells
Glenna Wink Foight et al.
ACS CHEMICAL BIOLOGY (2014)
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Peter E. Czabotar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
Zhi-Fu Tao et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
A New Bliss Independence Model to Analyze Drug Combination Data
Wei Zhao et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
Xi Wang et al.
GENES & DEVELOPMENT (2013)
Structure-guided design of a selective BCL-XL inhibitor
Guillaume Lessene et al.
NATURE CHEMICAL BIOLOGY (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
Matthew S. Davids et al.
BLOOD (2012)
Rapid engraftment of human ALL in NOD/SCID mice involves deficient apoptosis signaling
M. Queudeville et al.
CELL DEATH & DISEASE (2012)
Early Relapse in ALL Is Identified by Time to Leukemia in NOD/SCID Mice and Is Characterized by a Gene Signature Involving Survival Pathways
Lueder Hinrich Meyer et al.
CANCER CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program
Decheng Ren et al.
SCIENCE (2010)
BAX activation is initiated at a novel interaction site
Evripidis Gavathiotis et al.
NATURE (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Programmed anuclear cell death delimits platelet life span
Kylie D. Mason et al.
CELL (2007)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL
Loder Hinrich Meyer et al.
BLOOD (2006)
The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia
A Holleman et al.
BLOOD (2006)
Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells
JT Opferman et al.
SCIENCE (2005)
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
L Chen et al.
MOLECULAR CELL (2005)
分享论文
